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Vasopressin elicited a dose-dependent inhibition of ghtcagon-induced cAMP accumulation in isolated 
hepatocytes. This response was not diminished by incubation of cells with the calmodulin antagonists 
trifluoperazine or chlorpromazine and was only slightly reduced in Ca*+-depleted hepatocytes. Half- 
maximal inhibition of CAMP accumulation occurred at 8 x 10-r” M vasopressin, a dose which does not 
increase cytosolic Ca’+ in hepatocytes. Direct activation of adenylate cyclase by forskolin was significantly 
inhibited by vasopressin in Ca’+depleted cells. It is concluded that inhibition of hormone-induced CAMP 
accumulation by vasopressin in liver is not dependent on cellular Ca2’ mobilisation but may involve direct 
inhibition of adenylate cyclase. 
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1. INTRODUCTION 
Recent studies have revealed that the vasoactive 
peptide vasopressin can elicit a number of re- 
sponses in rat liver, including Ca2+ mobilization, 
phospholipid turnover and inhibition of hor- 
monally induced CAMP accumulation [l-5]. 
There is much evidence that the metabolic re- 
sponses to vasopressin in liver directly result from 
cellular Ca” mobilisation and elevation of cyto- 
solic Ca2’ [6]. Since inhibition of glucagon-in- 
duced CAMP formation has also been demonstra- 
ted in rat hepatocytes incubated in the presence of 
the Ca2+ ionophore A23 187 [5,7], it is possible that 
increases in cytosolic Ca2+ may play a primary role 
in CAMP inhibition by vasopressin, perhaps as a 
result of activation of Ca2+-calmodulin-dependent 
cAMP phosphodiesterase [g] . Alternatively, direct 
inhibition of adenylate cyclase by a Ca2+-indepen- 
dent mechanism could also mediate the response, 
as in the case of cr2-adrenergic agonists and 
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angiotensin II [4,9]. We here investigated the role 
of Ca2’ in v~opressin-induced CAMP inhibition 
and demonstrate that this response is not secon- 
dary to Ca” mobilisation, but occurs by an in- 
dependent mechanism. 
2. EXPERIMENTAL 
Parenchymal cells from the livers of fed male 
Sprague-Dawley rats (180-220 g body wt) were 
isolated and incubated as described [lot. 
Ca2+-depleted hepatocytes were prepared as in [5] 
and, when appropriate, Ca2+-repletion was achiev- 
ed by re-addition of 4 mM Ca2+ to Ca’+-depleted 
cells, 20 min prior to hormone addition. 
Hepatocyte CAMP levels were measured by 
radioimmunoassay of perchloric acid extracts as in 
1111. 
Arginine-vasopressin, angiotensin II, trifluo- 
perazine and chlorpromazine were from Sigma. 
Glucagon was a gift from Lilly (IN). A23187 and 
forskolin were from Calbiochem. 
~~45793/83/$3.# 0 1983 Federation of European Biochemi~ Societies 277 
Volume 163, number 2 FEBS LIYITERS November 1983 
3. RESULTS 
The data presented in fig. 1 demonstrate that, in 
isolated hepatocytes treated with lO_’ M glucagon, 
vasopressin (lO_’ M) markedly reduced the extent 
of CAMP accumulation. In contrast, vasopressin 
did not alter basal CAMP levels in hepatocytes 
(table 1, I4,5]). The ability of vasopressin to lower 
glucagon-induced CAMP accumulation was most 
evident in cells incubated in medium containing 
Ca”, where up to 35% inhibition could be achiev- 
ed at lo-’ M vasopressin (fig. 1). The response was 
significantIy (p < 0.025) attenuated when 
Ca’+-depleted cells were employed (fig. l), 
although under these conditions vasopressin still 
caused significant inhibition of glucagon-induced 
CAMP accumulation & < 0.025, fig. 1). These data 
suggest hat CAMP inhibition was not solely the 
consequence of cellular Ca2+-mobilisation. In sup- 
port of this, vasopressin was also observed to in- 
hibit phosphorylase activation in response to low 
doses of glucagon under conditions of 
Ca’+-depletion (not shown). 
Pre-incubation of hepatocytes with the 
calmodulin inhibitors trifluoper~ine and chlor- 
promazine at concentrations up to 100 yM, failed 
to diminish vasopressin’s ability to inhibit 
glucagon-induced CAMP accumulation (fig.2). 
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Fig.1. Effect of calcium depletion on the inhibition of 
CAMP accumulation by vasopressin. Cat+-depleted 
hepatocytes were prepared as described in section 2, and 
Ca*+ was added back to a proportion of the cells. 
Glucagon (lo-* M) and vasopressin (lo-’ M) were 
added and samples removed for CAMP measurements 
2 min later. Results are expressed as percentages of the 
maximal CAMP level in response to glucagon alone, and 
represent mean values rt SEM from 4 separate cell 
preparations each incubated in triplicate. Basal CAMP 
levels were not altered in Ca2’-depleted YS Ca2+-replete 
cells (0.36 f 0.06 pmol/mg cells) and under these 
conditions glucagon increased cAMP to 4.63 tt 
1.3 pmol/mg cells and 3.14 f 0.76 pmol/mg cells, 
respectively (mean values from 4 experiments). 
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Fig.2. Effect of calmodulin antagonists on vasopressin- 
mediated cAMP inhibition. Isolated hepatocytes were 
preincubated for 15 min with different concentrations of 
either trifluoper~ine or chlorpromazine as shown. After 
this time glucagon (lo-’ M) and vasopressin (lo-* M) 
were added and incubation continued for a further 
2 min, when samples were withdrawn for determination 
of CAMP content. Data are expressed as mean values + 
SEM for quadruplicate incubations from an experiment 
representative of two. 
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Since these agents did not alter the CAMP response 
to glucagon alone (not shown), the results indicate 
that calmodulin-dependent processes play no ma- 
jor role in the inhibitory action of vasopressin. 
The data presented in fig.3 demonstrate that in- 
hibition of glucagon-induced CAMP accumulation 
by vasopressin was dose-dependent with the half- 
maximal response being observed at a hormone 
concentration as low as 8 x 10-l’ M. 
The diterpene forskolin is a potent activator of 
adenylate cyclase in a variety of tissues [12] and 
caused a dose-dependent increase in CAMP levels 
in isolated hepatocytes (table 1). In Ca’+-depleted 
cells, which were employed to eliminate any 
Ca’+-mediated inhibition of CAMP accumulation, 
increases in CAMP in response to forskolin were 
markedly inhibited by vasopressin (table 1). The 
extent of this inhibition was similar to that induced 
by angiotensin II (table 1) which can directly in- 
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Fig.3. Dose-response curve for inhibition of glucagon- 
induced CAMP accumulation in hepatocytes, by 
vasopressin. Isolated hepatocytes were incubated with 
lo-’ M glucagon in the presence of increasing doses of 
vasopressin. Samples were withdrawn 2 min after 
hormone addition for determination of cell CAMP 
content. Results are expressed as percentages of the 
maximal CAMP response in the absence of vasopressin, 
and represent mean values f SEM obtained from 3 
separate cell preparations each replicated 6-times. 
Table 1 
Dose-response relationship for hepatocyte CAMP 
accumulation in response to forskolin 
[Forskolin] Cell CAMP content (pmol/mg cells) 
(M) Additions to medium 
Saline Vasopressin Angiotensin II 
(lo-* M) (lo-* M) 
0 1.94 2.04 1.95 
5 x lo-’ 1.77 
10-6 2.06 
5 x lO+j 3.02 
lo-’ 7.08 
2 x 1o-5 9.81 f 0.95 7.31 f 0.51= 
5 x 1O-5 12.75 + 1.37 8.14 f 0.95a 6.53 -+ 0.82b 
Ca2+-depleted hepatocytes were incubated with 
increasing concentrations of forskolin in the absence or 
presence of vasopressin or angiotensin II for 1 min, after 
which time samples were withdrawn into 0.6 N 
perchloric acid for measurement of CAMP content. Data 
are mean values obtained from triplicate incubations in 
an experiment representative of two. ’ p < 0.05, b p < 
0.01 vs forskolin alone 
hibit adenylate cyclase in liver plasma membranes 
t4,91* 
4. DISCUSSION 
It has been surmised for several years that treat- 
ment of isolated rat hepatocytes with vasopressin 
leads to an increase in the cytosolic Ca2+ concen- 
tration which then mediates the subsequent 
metabolic events associated with hormone stimula- 
tion [6]. Recently, direct evidence in support of 
this concept has been provided [l]. Vasopressin 
has also been shown to inhibit the CAMP response 
to glucagon in liver cells [4,5], and since ionophore 
A23187 also inhibits this response [5,7] under con- 
ditions where Ca2+-influx into the cell is enhanced 
[13], it seems possible that this action of 
vasopressin could also be the result of cellular 
Ca2+-mobilisation. One mechanism which might 
account for this effect, would be that Ca2+ 
mobilisation in response to the hormone causes ac- 
tivation of calmodulin-dependent CAMP 
phosphodiesterase, leading to enhanced degrada- 
tion of CAMP [8]. Such a mechanism has been im- 
plicated in part, in the ability of muscarinic 
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cholinergic agonists to antagonise hormone- 
stimulated CAMP accumulation in rat prostate 
gland [ 141 and in cultured fibroblasts [ 151. Pre- 
incubation of isolated hepatocytes with the 
calmodulin antagonists trifluoperazine and chlor- 
promazine, at concentrations sufficient to allow 
penetration into liver cells [16] and which inhibit 
calmodulin-dependent processes in other tissues 
(e.g., [17]), failed, however, to attenuate 
vasopressin-induced inhibition of CAMP ac- 
cumulation (fig.2). Furthermore, total depletion of 
the hormone-sensitive Ca2+ pool in hepatocytes 
(by treatment with EGTA, see [11,18]) also failed 
to prevent CAMP inhibition by vasopressin (fig. 1). 
It should be noted however, that under these con- 
ditions the extent of inhibition was reduced com- 
pared to that in controls to which Ca2+ had been 
added back (fig. 1). These data suggest, therefore, 
that cellular Ca2+ mobilisation in response to 
vasopressin plays only a relatively minor role in the 
mediation of CAMP inhibition. 
Further support for this suggestion derives from 
a comparison of the sensitivity of 
Ca2+-mobilisation and CAMP inhibition to the 
hormone. As shown in fig.3, the half-maximal 
concentration of vasopressin required for inhibi- 
tion of glucagon-induced CAMP formation was 
about 8 x lo-” M. In contrast, Ca’+-mobilisation 
and phosphorylase activation (which results from 
the increased cytosolic Ca*+ level [6,13]) require a 
5-fold greater concentration of vasopressin for 
half-maximal effects [ 13,181. Indeed, cytosolic 
Ca2+ is not significantly increased by the dose of 
vasopressin which mediates half-maximal effects 
on CAMP accumulation (fig. 1, [18]). 
An alternative mechanism by which vasopressin 
could antagonize hepatic CAMP accumulation is 
through inhibition of adenylate cyclase. In this 
respect, angiotensin II (a vasopressor hormone 
which, like vasopressin, causes both 
Ca’+-mobilisation and CAMP inhibition in liver; 
see (51) has been demonstrated to directly inhibit 
adenylate cyclase activity in liver plasma mem- 
branes [4,9]. It is possible, therefore, that, by 
analogy with angiotensin II, vasopressin may also 
cause a direct inhibition of hepatic adenylate 
cyclase. The data in table 1 are in accord with this 
contention. Forskolin is a generalised activator of 
adenylate cyclase [12] whose action can be in- 
hibited by a variety of hormones which exert a 
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negative control over adenylate cyclase [ 191. 
Vasopressin was here observed to lower forskolin- 
mediated CAMP increases in Ca2+-depleted 
hepatocytes, consistent with a direct inhibition of 
adenylate cyclase (table 1). In addition, angioten- 
sin II exerted a similar influence. 
These data are consistent with a direct effect of 
vasopressin to inhibit liver cell adenylate cyclase. 
In this respect it has been observed that the binding 
of hormones which inactivate adenylate cyclase to 
their receptors is modified by guanine nucleotides 
[20]. This has been demonstrated in liver for both 
angiotensin II and cYz-adrenergic agonists [4,20]. 
Furthermore, the binding of [3H]vasopressin to 
liver membranes is also decreased by GTP [21] 
consistent with a possible negative coupling at the 
level of adenylate cyclase. In one study [9], 
however, direct inhibition of liver plasma mem- 
brane adenylate cyclase activity by vasopressin was 
not observed under conditions where angiotensin 
II was inhibitory. It should be emphasized, 
however, that the conditions required to obtain ef- 
fects in that study were very stringent [9] and may 
have been inappropriate for the vasopressin 
response. In view of the differential sensitivity of 
cellular Ca’+-mobilisation and hormone-induced 
CAMP inhibition to vasopressin (fig.3, [18]) it is 
possible that different vasopressin receptors 
mediate these respective effects, as is the case for 
the a-adrenergic receptors. 
In conclusion, our data suggest hat the ability 
of vasopressin to lower hepatic CAMP levels is 
largely independent of cellular Ca’+-mobilisation 
and results from interaction with a receptor of 
higher affinity than that which induces 
Ca2+-mobilisation. This high affinity receptor may 
be directly linked to inhibition of adenylate 
cyclase. 
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